文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

气管内滴入布地奈德混合肺表面活性物质以提高极早产儿无支气管肺发育不良生存率:国际多中心随机PLUSS试验研究方案

Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial.
PubMed 文献 · Trials · 2023-05-09

PLUSS试验为国际多中心双盲随机试验,纳入出生<48小时、机械通气或接受无创呼吸支持且临床决定使用肺表面活性物质的极早产儿,比较气管内布地奈德(0.25 mg/kg)混合猪肺磷脂α(首次200 mg/kg,第二次100 mg/kg)与单用猪肺磷脂α(相同剂量)对36周矫正胎龄时无BPD生存率的影响。

要点

  • 极早产儿BPD发生率高,需有效安全的预防性治疗。
  • 气管内布地奈德混合肺表面活性物质可能提高无BPD生存率。
  • PLUSS试验主要结局为36周矫正胎龄时无BPD生存。

核心结论

  • 气管内布地奈德混合肺表面活性物质可能减少极早产儿BPD,并转化为儿童期健康获益。
  • 若该干预能提高无BPD生存且无严重不良反应,可立即引入临床实践。

研究设计与样本

  • 国际多中心、双盲、随机对照试验。
  • 纳入出生<48小时的极早产儿,需机械通气或接受无创呼吸支持且临床决定使用肺表面活性物质。
  • 干预组:气管内给予布地奈德(0.25 mg/kg)混合猪肺磷脂α(首次200 mg/kg,第二次100 mg/kg)。
  • 对照组:单用猪肺磷脂α(相同剂量)。

主要发现

  • 主要结局为36周矫正胎龄时无BPD生存。
  • 次要结局包括主要结局组分(死亡、36周矫正胎龄前或时BPD)、糖皮质激素潜在全身副作用、成本效益、至2岁儿童早期健康及2岁(矫正早产)神经发育结局。

临床怎么用

  • 若气管内布地奈德混合肺表面活性物质能提高无BPD生存且无严重不良反应,该易得干预可立即引入临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bronchopulmonary dysplasia (BPD), an inflammatory-mediated chronic lung disease, is common in extremely preterm infants born before 28 weeks' gestation and is associated with an increased risk of adverse neurodevelopmental and respiratory outcomes in childhood. Effective and safe prophylactic therapies for BPD are urgently required. Systemic corticosteroids reduce rates of BPD in the short-term but are associated with poorer neurodevelopmental outcomes if given to ventilated infants in the first week after birth. Intratracheal administration of corticosteroid admixed with exogenous surfactant could overcome these concerns by minimizing systemic sequelae. Several small, randomized trials have found intratracheal budesonide in a surfactant vehicle to be a promising therapy to increase survival free of BPD. METHODS: An international, multicenter, double-blinded, randomized trial of intratracheal budesonide (a corticosteroid) mixed with surfactant for extremely preterm infants to increase survival free of BPD at 36 weeks' postmenstrual age (PMA; primary outcome). Extremely preterm infants aged < 48 h after birth are eligible if: (1) they are mechanically ventilated, or (2) they are receiving non-invasive respiratory support and there is a clinical decision to treat with surfactant. The intervention is budesonide (0.25 mg/kg) mixed with poractant alfa (200 mg/kg first intervention, 100 mg/kg if second intervention), administered intratracheally via an endotracheal tube or thin catheter. The comparator is poractant alfa alone (at the same doses). Secondary outcomes include the components of the primary outcome (death, BPD prior to or at 36 weeks' PMA), potential systemic side effects of corticosteroids, cost-effectiveness, early childhood health until 2 years of age, and neurodevelopmental outcomes at 2 years of age (corrected for prematurity). DISCUSSION: Combining budesonide with surfactant for intratracheal administration is a simple intervention that may reduce BPD in extremely preterm infants and translate into health benefits in later childhood. The PLUSS trial is powered for the primary outcome and will address gaps in the evidence due to its pragmatic and inclusive design, targeting all extremely preterm infants regardless of their initial mode of respiratory support. Should intratracheal budesonide mixed with surfactant increase survival free of BPD, without severe adverse effects, this readily available intervention could be introduced immediately into clinical practice. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ( https://www.anzctr.org.au ), ACTRN12617000322336. First registered on 28th February 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Manley BJ, Kamlin COF, Donath S, et al. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial. Trials. 2023. PMID: 37161488. doi:10.1186/s13063-023-07257-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。